Motolimod

also known as VTX-2337 · VTX-378

Small molecule targets TLR8 via activation

Developed for: head and neck squamous cell carcinoma · primary peritoneal carcinoma · breast carcinoma · cancer · colorectal adenocarcinoma · cutaneous melanoma · fallopian tube cancer · fallopian tube carcinoma
+23 more
· hypopharynx squamous cell carcinoma · indolent B-cell non-Hodgkin lymphoma · larynx verrucous carcinoma · lymphoma · malignant epithelial tumor of ovary · metastatic squamous cell carcinoma · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · non-small cell lung carcinoma · oropharynx squamous cell carcinoma · ovarian Brenner tumor · ovarian cancer · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous cystadenocarcinoma · ovarian serous cystadenocarcinoma · pancreatic adenocarcinoma · renal cell carcinoma · salivary gland squamous cell carcinoma · squamous cell carcinoma · tongue cancer · undifferentiated ovarian carcinoma · verrucous carcinoma of oral cavity
Investigated by: Celgene Corporation · National Cancer Institute (NCI) · Gynecologic Oncology Group · Bristol-Myers Squibb · Cancer Research Institute, New York City · Ludwig Institute for Cancer Research
+5 more
· Mayo Clinic · MedImmune LLC · Presage Biosciences · Stanford University · University of Washington

Trials 11 · a red edge is where a trial was stopped

today NCT04272333 · Ph 0 NCT03906526 · Ph 1 NCT02650635 · Ph 1 NCT02431559 · Ph 1/2 NCT02124850 · Ph 1 NCT01836029 · Ph 2 NCT01666444 · Ph 2 NCT01289210 · Ph 1/2 NCT01334177 · Ph 1 NCT01294293 · Ph 1 NCT00688415 · Ph 1

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04272333	Oct 2021 → Mar 2022	head and neck squamous cell carcinoma	Presage Biosciences	Terminated	No outcome recorded
Phase 16 trials
Phase 1	NCT03906526	Jul 2019 → Jan 2022	squamous cell carcinoma	Celgene Corporation	Terminated	No outcome recorded
Phase 1	NCT02650635	Feb → Sep 2016	breast carcinoma, colorectal adenocarcinoma, cutaneous melanoma, non-small cell lung carcinoma +2	Mayo Clinic	Terminated	No outcome recorded
Phase 1	NCT02124850	Oct 2014 → Aug 2016	head and neck squamous cell carcinoma	Celgene Corporation	Terminated	No outcome recorded
Phase 1	NCT01334177	Jun 2011 → Jun 2014	hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5	University of Washington	Completed	No outcome recorded
Phase 1	NCT01294293	Mar 2011 → Jul 2014	fallopian tube carcinoma, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +4	Gynecologic Oncology Group	Completed	No outcome recorded
Phase 1	NCT00688415	Nov 2008 → Aug 2010	cancer, lymphoma	Celgene Corporation	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02431559	Dec 2015 → Dec 2018	ovarian cancer	Ludwig Institute for Cancer Research	Completed	No outcome recorded
Phase 1/2	NCT01289210	Jul → Nov 2011	indolent B-cell non-Hodgkin lymphoma	Celgene Corporation	Terminated	No outcome recorded
Phase 22 trials
Phase 2	NCT01836029	Oct 2013 → Apr 2016	head and neck squamous cell carcinoma	Celgene Corporation	Completed	No outcome recorded
Phase 2	NCT01666444	Oct 2012 → Jul 2016	fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma	Celgene Corporation	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	Motolimod	“VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications” PMID 26928328 ↗ Feb 2016 5 “Motolimod (VTX-2337), a selective small-molecule agonist of TLR8” PMID 27810904 ↗ Nov 2016 “Motolimod (VTX-2337)” NCT03906526 ↗ NCT02124850 ↗ NCT02431559 ↗ NCT04272333 ↗
Known as	VTX-2337	“Motolimod (VTX-2337)” NCT03906526 ↗ 7 NCT01334177 ↗ NCT01289210 ↗ NCT01836029 ↗ NCT01666444 ↗ NCT01294293 ↗ NCT00688415 ↗ NCT02650635 ↗
Known as	VTX-378	ChEMBL registry synonym — accepted as the source's own label CHEMBL3301618 ↗
Action	Activate	“TLR8 Agonist” NCT01289210 ↗
Modality	Small molecule	“the Small Molecule TLR8 Agonist VTX-2337” NCT01289210 ↗
Route	Other	“administered intratumorally” NCT01289210 ↗
Target	TLR8	“Small Molecule TLR8 Agonist” NCT01289210 ↗